Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
IMRX Stock | USD 2.06 0.07 3.29% |
Slightly above 54% of Immuneering Corp's investor base is interested to short. The analysis of the overall investor sentiment regarding Immuneering Corp suggests that many traders are impartial. Immuneering Corp's investing sentiment can be driven by a variety of factors including economic data, Immuneering Corp's earnings reports, geopolitical events, and overall market trends.
Immuneering |
- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabinenab-paclitaxel, complete or partial responses have been observed in the first two patients to date, for an initial response rate of 40 percent and an initial disease control rate of 80, with all five patients continuing on treatment - - Initial data are at 240 mg QD of IMM-1-104 additional patients have now been dosed at 320 mg QD in this arm IMM-1-104 has been well-tolerated to date in com
Read at finance.yahoo.com
Immuneering Corp Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Immuneering Corp can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Immuneering Corp Fundamental Analysis
We analyze Immuneering Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immuneering Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immuneering Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Immuneering Corp is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Immuneering Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immuneering Corp stock to make a market-neutral strategy. Peer analysis of Immuneering Corp could also be used in its relative valuation, which is a method of valuing Immuneering Corp by comparing valuation metrics with similar companies.
Peers
Immuneering Corp Related Equities
KRON | Kronos Bio | 10.34 | ||||
LRMR | Larimar Therapeutics | 7.44 | ||||
GOSS | Gossamer Bio | 6.06 | ||||
GLUE | Monte Rosa | 5.93 | ||||
ELVN | Enliven Therapeutics | 4.35 | ||||
CMPX | Compass Therapeutics | 3.31 | ||||
NVCT | Nuvectis Pharma | 2.52 | ||||
CGEM | Cullinan Oncology | 2.51 | ||||
CNTA | Centessa Pharmaceuticals | 1.73 | ||||
IVA | Inventiva | 1.52 | ||||
PMVP | Pmv Pharmaceuticals | 0.63 | ||||
NAMS | NewAmsterdam Pharma | 0.19 | ||||
IKNA | Ikena Oncology | 1.17 | ||||
CELC | Celcuity LLC | 1.53 | ||||
REPL | Replimune | 2.29 | ||||
LYRA | Lyra Therapeutics | 5.00 |
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.